ACADIA Pharmaceuticals Inc.
 (ACAD)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Fri, Feb. 12, 7:38 AM
    • Gilead Sciences (NASDAQ:GILD) initiated with Outperform rating and $120 (37% upside) price target by Oppenheimer.
    • CareDx (NASDAQ:CDNA) initiated with Buy rating and $12 (137% upside) price target by Janney Capital.
    • Shire plc (NASDAQ:SHPG) initiated with Neutral rating by Guggenheim.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Buy rating and $104 (95% upside) price target by H.C. Wainwright.
    • Depomed (NASDAQ:DEPO) initiated with Buy rating and $22 (38% upside) price target by UBS.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $40 (128% upside) price target by Bank of America.
    • Leerink restarts coverage on eight stocks: four Outperforms: Alexion Pharmaceuticals (NASDAQ:ALXN); Regeneron Pharmaceuticals (NASDAQ:REGN); Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (GILD); four Market Performs: Celgene (NASDAQ:CELG); Biogen (NASDAQ:BIIB); Medivation (NASDAQ:MDVN) and Amgen (NASDAQ:AMGN).
    • TESARO (NASDAQ:TSRO) initiated with Buy rating by Lake Street.
    • AbbVie (NYSE:ABBV) initiated with Outperform rating by William Blair.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Buy with $38 (41% upside) price target by Cantor Fitzgerald.
    • Shire plc (SHPG) upgraded to Outperform with price target of $240 (59% upside) by RBC.
    • Amedisys (NASDAQ:AMED) upgraded to Outperform with $40 (15% upside) price target by Oppenheimer.
    • Smith & Nephew (NYSE:SNN) downgraded to Neutral from Buy by UBS. Price target lowered to 1,100p (4% upside) from 1,250p.
    • Quidel (NASDAQ:QDEL) downgraded to Hold from Buy by Canaccord. Price target lowered to $18 (18% upside) from $22.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) downgraded Neutral from Overweight by JP Morgan. Price target lowered to $5 (201% upside) from $16.
    | Fri, Feb. 12, 7:38 AM | 9 Comments
  • Mon, Jan. 25, 10:39 AM
    • ACADIA Pharmaceuticals (ACAD +1.1%) appoints James (Randy) Owen, M.D., as SVP, Clinical Development and Chief Medical Officer. Previously, he was VP, U.S. Clinical Affairs at Lundbeck LLC.
    | Mon, Jan. 25, 10:39 AM | 29 Comments
  • Thu, Jan. 7, 7:01 AM
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) prices its public offering of 10,344,827 shares of common stock at $29 per share. Underwriters over-allotment is an additional 1,551,724 shares. Closing date is January 12.
    • Shares are down 4% premarket on light volume.
    | Thu, Jan. 7, 7:01 AM | 4 Comments
  • Tue, Jan. 5, 5:41 PM
    | Tue, Jan. 5, 5:41 PM | 5 Comments
  • Tue, Jan. 5, 4:19 PM
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) commences a $300M public offering of common stock. Price, volume and terms have yet to be announced.
    | Tue, Jan. 5, 4:19 PM | 31 Comments
  • Nov. 6, 2015, 5:38 PM
    • Top gainers, as of 5.25 p.m.: IHG +4.5%. CLLS +4.0%. WTW +4.4%.
    • Top losers, as of 5.25p.m.: ERII -2.4%. TS -2.2%. GFI -1.9%. ACAD -1.7%. ARMH -1.0%.
    | Nov. 6, 2015, 5:38 PM | 17 Comments
  • Nov. 5, 2015, 4:04 PM
    • ACADIA Pharma (NASDAQ:ACAD): Q3 EPS of -$0.39 beats by $0.01.
    • Revenue of $0.04M (+100.0% Y/Y) misses by $0.02M.
    | Nov. 5, 2015, 4:04 PM
  • Nov. 4, 2015, 5:35 PM
  • Nov. 2, 2015, 9:00 AM
    • The FDA accepts under Priority Review ACADIA Pharmaceuticals' (NASDAQ:ACAD) New Drug Application (NDA) for Breakthrough Therapy-tagged NUPLAZID (pimavanserin) for the treatment of Parkinson's disease (PD) psychosis. The PDUFA date is Sunday, May 1, so the agency's decision should happen no later than Friday, April 29.
    • NUPLAZID is a non-dopaminergic antipsychotic that acts as a selective serotonin inverse agonist that preferentially targets 5-HT2A receptors. About 40% of the 1M Americans with PD have psychosis, characterized by hallucinations and delusions, diminished quality of life and significant caregiver burden.
    • Breakthrough Therapy status allows for more intensive guidance from the FDA, the involvement of more senior agency personnel and a rolling review of the NDA. Priority Review shortens the review clock to six months from the usual ten.
    • Shares are up 8% premarket on increased volume.
    | Nov. 2, 2015, 9:00 AM | 29 Comments
  • Sep. 3, 2015, 9:12 AM
    | Sep. 3, 2015, 9:12 AM | 1 Comment
  • Sep. 3, 2015, 8:16 AM
    • Acadia Pharmaceuticals (NASDAQ:ACAD) appoints Steve Davis as President & CEO. He has served under an "interim" status since March when he succeeded the retiring Uli Haskell, Ph.D.
    | Sep. 3, 2015, 8:16 AM | 1 Comment
  • Sep. 3, 2015, 8:12 AM
    • Acadia Pharmaceuticals (NASDAQ:ACAD) is up 10% premarket on modest volume in response to the company's filing of a New Drug Application (NDA) seeking approval for Breakthrough Therapy-tagged NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease. The company also requested Priority Review status which will reduce the review clock to six months from ten, if granted.
    • NUPLAZID is a selective serotonin inverse agonist that targets 5-HT2A receptors that play a key role in psychosis.
    | Sep. 3, 2015, 8:12 AM | 17 Comments
  • Aug. 31, 2015, 4:08 PM
    • PTC Therapeutics (PTCT -6.2%) initiated with Buy rating and $90 (135% upside) price target by Citi.
    • Patterson Companies (PDCO -1.1%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $54 (18% upside) from $48.
    • Acadia Pharmaceuticals (ACAD -4.1%) upgraded to Overweight from Neutral with a price target of $48 (30% upside) by Piper Jaffray.
    • Boston Scientific (BSX -1.9%) upgraded to Buy from Neutral with a $20 (19% upside) price target by Goldman Sachs.
    • CR Bard (BCR -1.8%) upgraded to Buy from Neutral with a $220 (14% upside) price target by Goldman Sachs.
    • Sarepta Therapeutics (SRPT -2.7%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $48 (34% upside) from $28.
    • Bristol-Myers Squibb (BMY -1.8%) upgraded to Neutral from Underweight by Piper Jaffray. Price target maintained at $61 (2% upside).
    • MacroCure (MCUR -3.7%) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $5 (63% upside) from $15.
    | Aug. 31, 2015, 4:08 PM | 4 Comments
  • Aug. 27, 2015, 9:14 AM
    | Aug. 27, 2015, 9:14 AM | 4 Comments
  • Aug. 21, 2015, 5:36 PM
    • Top gainers, as of 5.25 p.m.: PES +13.0%. RCAP +9.8%. SPTN +7.6%. EPE +7.0%. ACAD +6.5%.
    • Top losers, as of 5.25p.m.: VTL -74.0%. TGH -5.6%. CLD -3.6%. INVN -2.9%. REXX -2.2%.
    | Aug. 21, 2015, 5:36 PM | 2 Comments
  • Aug. 7, 2015, 3:30 PM
    • Acadia Pharmaceuticals (ACAD -12.1%) downgraded to Neutral from Overweight by Pipe Jaffray. Price target raised to $48 (21% upside) from $39.
    | Aug. 7, 2015, 3:30 PM | 10 Comments
Company Description
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Sector: Healthcare
Industry: Biotechnology
Country: United States